Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|September 8, 2016
DSM Nutritional Products to Release New Technology at CPhI
Author(s)Pharmaceutical Technology Editors
The company will be releasing its new 3C technology for omega 3 EPA and DHA at CPhI Worldwide.
Advertisement
On July 27, 2016, DSM Nutritional Products announced that it will be introducing its 3C technology for omega-3 EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) at CPhI Worldwide 2016. The 3C technology delivers highly concentrated and customizable combinations of EPA and DHA for both pharmaceutical and food supplement applications. Visitors to DSM Nutritional Products at stand S310 during CPhI can learn about the omega-3 EPA/DHA status in individual countries. Prototypes will be available to demonstrate how the high EPA/DHA concentrations offered by 3C technology make it possible to achieve a much smaller capsule size.
Source: DSM Nutritional Products
Advertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
PharmTech’s Weekly Roundup—September 25, 2026
4
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
5